About N-of-One
N-of-One is a Healthcare company based in Lexington (United States) founded in 2008, and was acquired by Qiagen in January 2019. Molecular profiles are analyzed for clinical decision support in oncology. N-of-One has raised $17.75 million across 6 funding rounds from investors including Philips, Qiagen and Excel Venture Management. The company was acqui-hired. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Denali Therapeutics, Castle Biosciences and Juno Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
N-of-One was founded in 2008 and is based in Lexington, United States. Operations focus on the healthcare sector, where tumor molecular profiles are interpreted to guide physicians in diagnostics and treatments. Services include Precision Insights for NGS panel reports and TrialMatch for matching patients to clinical trials based on molecular data. Decision support is provided to clinicians without functioning as a diagnostic lab or bioinformatics provider.
- Headquarters Lexington, United States
- Stage Acquired
- SectorsHealthcare
- Website n-of-one.com
- Social LinkedIn X
- Acquired by Qiagen (Jan 2019)
Funding Insights of N-of-One
N-of-One has successfully raised a total of $17.75M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $7 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $17.75M
- Total Rounds 6
- Last Round Series B — $7M
- Investors Count 2
All 6 funding rounds of N-of-One with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2017 | $7M | Series B | – | – | – |
| Jul 2016 | $7M | Series B | – | – | |
| Jan 2016 | $3M | Series B | – | – | – |
| Jan 2014 | $2M | Debt – Conventional | – | – | – |
| Aug 2011 | Debt – Conventional | – | – | – | |
| Aug 2011 | $748,955 | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in N-of-One
N-of-One has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Philips, Qiagen and Excel Venture Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early to late stage VC firm investing in the US | excelvm.com | Boston, United States | ||
Venture capital firm | allumiaventures.com | Seattle, United States | ||
Products and reagents for molecular diagnostic assays are supplied. | 1984 | qiagen.com | Hilden, Germany | |
Diversified products are provided across health, lighting, and consumer sectors. | 1891 | philips.com | Amsterdam, Netherlands |
Investor details for N-of-One
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Competitors of N-of-One
N-of-One has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, Castle Biosciences and Juno Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.67M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. |
Detailed competitors of N-of-One
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as N-of-One (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about N-Of-One
Complete news archive for N-of-One
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about N-of-One
N-of-One was founded in 2008 and raised its 1st funding round 3 years after it was founded.
N-of-One is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
N-of-One is a funded company, having raised a total of $17.75M across 6 funding rounds to date.
N-of-One was founded in 2008 and is based in Lexington, United States. Operations focus on the healthcare sector, where tumor molecular profiles are interpreted to guide physicians in diagnostics and treatments. Services include Precision Insights for NGS panel reports and TrialMatch for matching patients to clinical trials based on molecular data. Decision support is provided to clinicians without functioning as a diagnostic lab or bioinformatics provider.
N-of-One's top competitors include Juno Therapeutics, Denali Therapeutics and Castle Biosciences.
N-of-One has 4 investors. Key investors include Philips, Qiagen, Excel Venture Management, and Allumia Ventures.
Yes. N-of-One was acquired by Qiagen in January 2019.